Skip to main content
Satellos Bioscience Inc. logo

Satellos Bioscience Inc. — Investor Relations & Filings

Ticker · MSCL ISIN · CA80401L3083 TSX Professional, scientific and technical activities
Open in API
Filings indexed 216 across all filing types
Latest filing 2025-11-18 Board/Management Inform…
Country CA Canada
Listing TSX MSCL

About Satellos Bioscience Inc.

https://satellos.com/

Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing regenerative small molecule therapeutics for degenerative muscle diseases, primarily Duchenne muscular dystrophy (DMD). The company's core mission is to restore the body's natural ability to regenerate muscle, addressing the failure of muscle repair inherent in these conditions. Satellos utilizes a novel approach rooted in muscle biology, focusing on restoring the asymmetric division of muscle stem cells (satellite cells), a process disrupted by the absence of dystrophin in DMD. Their strategy involves targeting the AAK1 protein to reactivate the natural repair mechanism. The lead therapeutic candidate, SAT-3247, is currently advancing into a Pediatric Phase 2 clinical study for DMD.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Board/Management Information Classification · 1% confidence The document is a 'Material Change Report' (Form 51-102F3) filed by Satellos Bioscience Inc. The primary content of the report is the formal announcement of the appointment of a new member to the company's board of directors (Mark Nawacki). According to the provided filing definitions, announcements regarding changes in the board of directors are classified under 'Board/Management Information' (MANG).
2025-11-18 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release issued by Satellos Bioscience Inc. announcing the publication of scientific research in Nature Communications. It does not fit into financial reporting categories like 10-K, IR, or ER, nor does it represent a corporate governance or shareholder event. As it is a general corporate announcement regarding research and development progress that does not fall into the other specific categories provided, it is classified as a Regulatory Filing (RNS).
2025-11-18 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Consolidated Interim Financial Statements' for Satellos Bioscience Inc. for the three and nine months ended September 30, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Shareholders' Equity, and Statement of Cash Flows) along with detailed explanatory notes. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2025
2025-11-14 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is explicitly titled 'Management’s Discussion and Analysis' (MD&A) for Satellos Bioscience Inc. for the three and nine months ended September 30, 2025. It contains detailed management commentary on financial results, business operations, forward-looking statements, and risk factors. This is a standard quarterly management report, which falls under the 'Management Reports' (MDA) category.
2025-11-14 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Certification of Interim Filings' (Form 52-109F2) signed by the CEO. This is a regulatory requirement under National Instrument 52-109 to certify the accuracy of interim financial reports and MD&A. Since it is a standalone regulatory certification document rather than the interim report itself or a general announcement, it falls under the 'Regulatory Filings' category as it does not fit into the specific financial report or management report categories.
2025-11-14 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Certification of Interim Filings' (Form 52-109F2) signed by the CFO. This is a regulatory requirement under National Instrument 52-109 for certifying the accuracy of interim financial reports and MD&A. Since it is a standalone regulatory certification document rather than the interim report itself or a general announcement, it falls under the category of Regulatory Filings.
2025-11-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.